Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics 2024年第一季度GAAP每股收益美元（0.75美元）超过预期（1.09美元），销售额为16.77亿美元，低于16.88万美元的预期
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last year.
Plus Therapeutics（纳斯达克股票代码：PSTV）公布的季度亏损为每股0.75美元（0.75美元），比分析师普遍预期的1.09美元（1.09美元）高出31.19％。这比去年同期每股亏损2.07美元（2.07）增长了63.77％。该公司公布的季度销售额为16.77亿美元，比分析师普遍预期的16.88万美元低0.62％。这比去年同期的50.6万美元销售额增长了231.42％。